Are Corticosteroids Beneficial for Sepsis and Septic Shock? Based on Pooling Analysis of 16 Studies

Yang-Yang Yao¹, Lu-Lu Lin¹,², Hui-Yun Gu², Jun-Yi Wu¹, Yu-Ming Niu¹,²* and Chao Zhang¹*

¹ Center for Evidence-Based Medicine and Clinical Research, Taihe Hospital, Hubei University of Medicine, Shiyan, China,
² Department of Intensive Care Unit, Taihe Hospital, Hubei University of Medicine, Shiyan, China

**Background:** A host of systematic reviews and meta-analyses were carried out to estimate the role of corticosteroids in sepsis and septic shock. Discordant opinions were investigated to determine whether patients who experienced sepsis and septic shock could benefit from corticosteroids treatment. Our purpose is to perform a systematic review of overlapping meta-analyses, to explore the role of corticosteroids in the treatment of sepsis and septic shock.

**Method:** Ovid MEDLINE, EMBase, Cochrane Database of Systematic Reviews, and LILACS were searched for eligible studies. Two authors individually extracted the relevant data and evaluated the quality of the meta-analysis using A MeaSurement Tool to Assess systematic Reviews 2 (AMSTAR 2) and ROBIS. The Jadad decision algorithm was implemented to identify the meta-analyses that offered the optimal level of evidence.

**Result:** Sixteen meta-analyses met the eligibility criteria. None of the studies that reported mortality illustrated a significant improvement on mortality (14-day and 90-day), but a 28-day mortality on a long course of a low dose corticosteroids was described. Only four studies stated that a long course of low-dose corticosteroids had advantageous effect on 28-day mortality. A meta-analysis by Fang et al. was regarded as the highest level of evidence in the Jadad decision algorithm among the meta-analyses that were investigated in this systematic review.

**Conclusion:** The 28-day mortality was reduced, as well as the mortality in the ICU and hospital and the length of stay in the ICU, using a long course of low-dose corticosteroids. This was demonstrated by a meta-analysis of the current optimal available evidence. Additionally, significant improvements on the adverse events of hyperglycemia and hypernatraemia have been made.

**Keywords:** septic, corticosteroids, mortality, overlapping analysis, AMSTAR 2

**INTRODUCTION**

Sepsis is one of the oldest and most elusive medical syndromes (Monti et al., 2015), and is a major reason for hospital mortality and critical disease (Cohen et al., 2015; Finfer and Machado, 2016). Sepsis has been reported to affect almost 300 out of 100,000 people in the USA (Cawcutt and Peters, 2014), and has resulted in over 200,000 deaths (Angus et al., 2001). The increasing mortality from...
sepsis and its complications have become a major public health problem worldwide and causes damage to patients regardless of their age (Suffredini and Munford, 2011). The definition of sepsis is constantly being updated since it was initially defined at a 1991 consensus conference (3), to its current definition by the Society of Critical Care Medicine (SCCM) (Makic and Bridges, 2018). At present, septic shock is defined as a subset of sepsis that involves aspects underlying circulatory and cellular or metabolic abnormalities, which can increase mortality triggered by a multifaceted amplified infection (Shankar-Hari et al., 2016; Singer et al., 2016; Napolitano, 2018).

Routine treatment for sepsis and septic shock include source control, fluid resuscitation, broad-spectrum antimicrobials, and vasopressors as needed (Long and Koyfman, 2017). Out of the above treatments, corticosteroids are also an important adjunctive therapy for sepsis and septic shock. Glucocorticoids are therefore the representative medicine for adjunctive therapy in patients who suffer from sepsis and septic shock, and the use of glucocorticoids attenuates the proinflammatory response, limits the anti-inflammatory response and preserves innate immunity (Marik, 2018). Exogenous glucocorticoids are extensively available given their low cost and certified capability to inhibit the inflammatory cascade (Annane et al., 2017). However, from 1976 to today, the use of corticosteroids for sepsis and septic shock has been debatable (Cawcutt and Peters, 2014; Long and Koyfman, 2017). There are two factions (salutary or detrimental effects on treatment) who are at odds over the administration of corticosteroids in sepsis and septic shock, that is, almost all studies stated that corticosteroids reduce mortality (Annane et al., 2004; Annane et al., 2009; Annane et al., 2015), while a few studies presented opposing view (Authors, 1987; Bone et al., 1987; Sprung et al., 1984; Wang et al., 2014). Additionally, meta-analyses and systematic reviews that have been published recently have suggested that a long course of low dose corticosteroids can actually save patients from sepsis and septic shock (Fang et al., 2019) (Annane et al., 2004; Annane et al., 2015). Thus, we hypothesized that a long course of low dose corticosteroids could improve the 28-day mortality of patients with sepsis and septic shock.

To investigate our hypothesis, we performed an overlapping meta-analysis aimed to elucidate the role of corticosteroids for patients with sepsis and septic shock and identified the most potent corticosteroids regimen for patient care. We also looked for evidence that gave rise to the controversial findings that have been observed for corticosteroids therapy.

**METHOD**

**Literature Search**

Several databases, including Ovid MEDLINE, EMBase, Cochrane Database of Systematic Reviews and Latin American Caribbean Health Sciences Literature (LILACS), were systematically searched for current studies that adhere to our eligibility criteria. We initiated the literature search on 20 April 2019 to identify published systematic reviews and meta-analyses. Two authors were responsible for screening the studies to obtain full manuscripts, as well as the titles and abstracts. To ensure completeness and accuracy of this review, two reviewers participated in the entire literature search process without interfering with one another. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) (Moher et al., 2009) was performed.

**Literature Selection and Exclusion**

The inclusion criteria were as follows: 1) systematic review or meta-analysis that described relative outcome(s) associated with corticosteroids (glucocorticoids) for septic shock and sepsis, 2) a population of adults with shock and septic shock, 3) no restriction of language and publication status 4) studies must include randomized controlled trials RCTs, 5) the definitions of corticosteroids dose and course were based on included primary systematic reviews and meta-analyses.

The exclusion criteria were as follows: 1) data unavailable 2) studies involved other diseases to septic shock and septic shock and did not separate the objective data 3) a pediatric population 4) the mortality effect size was reported as a rate difference.

**Data Extraction**

The following data was extracted from each study: 1) primary author, 2) date of publication, 3) date of last literature search, 4) number of included studies and included RCTs, 5) restriction of publication language and publication status, 6) search databases, 7) included primary studies 8) primary outcomes, including mortality at different days, 9) secondary outcomes, including the length of stay in the ICU and duration of hospital admission, shock reversal at day 7 and day 28, the incidence of adverse events, etc.

**Interventions**

Meta-analyses and systematic reviews were used to compare treatment groups (all types of steroids such as hydrocortisone, methylprednisolone, betamethasone, fludrocortisones, dexamethasone, cortisone and other corticosteroids) with standard treatment (antibiotics, fluid replacement, inotropes, vasopressors, mechanical ventilation, renal replacement therapy) or a placebo. Moreover, when feasible, all doses and the length of administration, regardless of continuous or intermittent administration, were compared for corticosteroids.

**Assessment of Methodological Quality**

To identify high quality systematic reviews, A MeaSurement Tool to Assess systematic Reviews 2 (AMSTAR 2) (Shea et al., 2017), updated in 2017, added four domains and removed one domain, resulting in the inclusion of 16 items. In contrast to departed AMSTAR (Shea et al., 2007), the AMSTAR 2 tool modified individual item ratings emphasizing the potential impact of an inadequate rating for a single item, rather than an overall score.

**Application of ROBIS**

ROBIS (Whiting et al., 2016) is a tool that is used to assess the risk of bias in systematic reviews, ROBIS is completed in three
phases as follows: 1) assess relevance (optional) by estimating the extent to match between target question and systematic review question, 2) identify concerns with the review process containing study eligibility criteria; identification and selection of studies; data collection and study appraisal and synthesis and findings, and 3) judge risk of bias in the review, which focused on the risk of bias caused by the conduct of reviews. This is a domain-based approach with signaling questions, following the most recent methods to assess the risk of bias.

**Heterogeneity Assessment**

Heterogeneity describes an inconsistency among included studies, which is likely to affect the conclusion and result of the studies. In this overlapping meta-analysis, heterogeneity across the studies involved was tested using the I² static (Higgins et al., 2003), which describes the percentage of total variation across studies that is attributable to heterogeneity rather than chance. The three levels, low, moderate, and high, were assigned according to the degree of heterogeneity via I² values of 25%, 50%, and 75%, respectively.

**Application of Jadad Decision Algorithm**

The Jadad Decision Algorithm (Jadad et al., 1997) is an adjunct decision tool for interpreting discordance among meta-analyses from the six aspects, including a clinical question, study selection and inclusion, data extraction, assessment of the study quality, and the assessment of the ability to combine studies and statistical methods for data synthesis. In general, the Jadad Decision Algorithm has been used widely for determining the current best meta-analysis or systematic reviews, by comparing populations, interventions, outcome measures, and the settings examined.

**RESULTS**

**Search Results**

The 2020 studies were found through an electrical search and only 16 studies (Annane et al., 2004; Burry and Wax, 2004; Minneci et al., 2004; Annane et al., 2009; Sligl et al., 2009; Moran et al., 2010; Wang et al., 2014; Annane et al., 2015; Volbeda et al., 2015; Lyu et al., 2018; Ni et al., 2018; Rochweg et al., 2018; Rygard et al., 2018; Xu et al., 2018; Zhu et al., 2018; Fang et al., 2019) met the inclusion criteria in this overlapping meta-analysis. These 16 studies were published between 2004 (Annane et al., 2004) and 2019 (Lyu et al., 2018; Ni et al., 2018; Rochweg et al., 2018; Rygard et al., 2018; Xu et al., 2018; Zhu et al., 2018; Fang et al., 2019), and recruited from 505 patients (Burry and Wax, 2004) to 10,194 patients (Rochweg et al., 2018). Additionally, the number of primary studies varied from nine (Xu et al., 2018) to 42 (Rochweg et al., 2018). Among these included studies, 14 studies declared no conflict of interest in their reviews (Annane et al., 2004; Minneci et al., 2004; Sligl et al., 2009; Moran et al., 2010; Wang et al., 2014; Annane et al., 2015; Volbeda et al., 2015; Lyu et al., 2018; Ni et al., 2018; Rochweg et al., 2018; Rygard et al., 2018; Xu et al., 2018; Zhu et al., 2018; Fang et al., 2019), and only two studies were unclear about the conflict of interest (Burry and Wax, 2004; Annane et al., 2009). The details of the primary studies from the systematic reviews that were included are shown in Supplementary Table 2. The particular information of included systematic reviews can be found in Table 1 and a flow diagram of the literature screen that is shown in Figure 1.

**Search Methodology**

Confining to English language was reported in only two studies (Sligl et al., 2009; Moran et al., 2010), and four studies (Minneci et al., 2004; Sligl et al., 2009; Moran et al., 2010; Zhu et al., 2018) reported that their the publication status was restricted as published studies. All the studies (Annane et al., 2004; Burry and Wax, 2004; Minneci et al., 2004; Annane et al., 2009; Sligl et al., 2009; Moran et al., 2010; Wang et al., 2014; Annane et al., 2015; Volbeda et al., 2015; Lyu et al., 2018; Ni et al., 2018; Rochweg et al., 2018; Rygard et al., 2018; Xu et al., 2018; Zhu et al., 2018; Fang et al., 2019) used PubMed/Medline, and both EMBase and Cochrane Central Register of Controlled Trials (CENTRAL). The Cochrane Library to search literature was used by all studies except Minneci et al (Minneci et al., 2004), LILACS was used by five meta-analyses (Annane et al., 2004; Annane et al., 2009; Wang et al., 2014; Annane et al., 2015; Rochweg et al., 2018), however, only four studies (Annane et al., 2004; Annane et al., 2009; Wang et al., 2014; Annane et al., 2015) searched the Cochrane infectious diseases group’s trial register. The electronic literature search strategies are shown in detail in Supplementary Table 1.

**Outcome Measures**

The primary outcome chiefly included mortality at day 28, especially for mortality due to a long course of low dose corticosteroids, as well as 90-day mortality. Mortality at 30 days was classified as 28-day mortality in this review, since only one study reported this (Volbeda et al., 2015). A mortality subgroup analysis was preformed according to the number of days, ranked in ascending order (14 days to 1 year), and different courses with diverse doses. In addition, the mortality of ICU and hospital admissions, the length of stay in the ICU and hospital, and adverse events and shock reversal, were investigated as secondary outcomes. The length of stay in the ICU and hospital and shock reversal on day 7 or day 28, also served a crucial role in assessing the benefit of corticosteroids in treating septic shock and sepsis in recent years. Meanwhile, we cannot ignore corticosteroids-associated adverse events, which involve gastroduodenal bleeding or gastro-intestinal bleeding, superinfection or secondary infections, hyperglycemia, hypernatriaemia, neuromuscular weakness, and so on. All of the outcomes of each meta-analysis or systematic review can be found in Supplementary Tables 3 and 4.

**Study Quality and Validity**

AMSTAR 2—an updated appraisal instrument for high quality meta-analyses, underlines critical domains rather than the total score, and the details of individual studies are presented in Table 2. We investigated the overall rating confidence of
TABLE 1 | Description of included studies.

| Meta-analysis       | Date of publication | Date of last literature search | No. of included studies (RCT) | Definition of Dose                        | Definition of Course |
|---------------------|---------------------|-------------------------------|------------------------------|-------------------------------------------|----------------------|
| Annane et al., 2004 | 2004/08/02          | 2003/08                       | 16(15)                       | High dose: ≥300 mg/day; Low dose: <300 mg/day | Short course: <5 days; |
|                     |                     |                               |                              |                                           | Long course: ≥5 days |
| Burry and Wax, 2004 | 2004/01/23          | 2003/03                       | 6(6)                         | Low dose: 200–300 mg/     | NR                  |
| Minneci et al., 2004| 2004/07             | 2003/12                       | 14(14)                       | Unclear                                  | Unclear             |
| Annane et al., 2009 | 2009/06/10          | 2009/03                       | 22(17)                       | High dose: ≥300 mg/day; Low dose: <300 mg/day | Short course: <5 days; |
|                     |                     |                               |                              |                                           | Long course: ≥5 days |
| Sigi et al., 2009   | 2009/06/2           | 2008/12                       | 8(8)                         | Unclear                                  | Unclear             |
| Morlan et al., 2010 | 2010/07/13          | 2008/09                       | 14(14)                       | High dose: ≥1,000 mg/day; Low dose: <1,000 mg/day | NR                  |
| Wang et al., 2014   | 2014/02             | 2012/05                       | 8(8)                         | High dose: ≥300 mg/day; Low dose: <300 mg/day | Short course: <5 days; |
|                     |                     |                               |                              |                                           | Long course: ≥5 days |
| Vobeda et al., 2015 | 2015/06/23          | 2015/02/18                    | 35(35)                       | High dose: ≥500 mg/day; Low dose: <500 mg/day | NR                  |
| Annane et al., 2015 | 2015                | 2014/10                       | 33(33)                       | High dose: ≥400 mg/day; Low dose: <400 mg/day | NR                  |
| Rochwerg et al., 2018 | 2018               | 2018/01/10                    | 42(42)                       | High dose: ≥400 mg/day; Low dose: <400 mg/day | Short course: <3 days; |
|                     |                     |                               |                              |                                           | Long course: ≥3 days |
| Rygard et al., 2018 | 2018                | 2018/03/03                    | 22(22)                       | High dose: ≥500 mg/day; Low dose: <500 mg/day | NR                  |
| Xu et al., 2018     | 2018/04/10          | 2017/10/23                    | 9(9)                         | High dose: ≥500 mg/day; Low dose: <500 mg/day | Short course: <3 days; |
|                     |                     |                               |                              |                                           | Long course: ≥3 days |
| Zhu et al., 2018    | 2018                | 2018/03/24                    | 18(18)                       | Unclear                                  | Unclear             |
| Fang et al., 2019   | 2018/12/21          | 2018/08/10                    | 37(37)                       | High dose: ≥400 mg/day; Low dose: <400 mg/day | Short course: <4 days; |
|                     |                     |                               |                              |                                           | Long course: ≥4 days |
| Lyu et al., 2018    | 2018/09/5           | 2018/03/07                    | 13(13)                       | High dose: ≥200 mg/day; Low dose: <200 mg/day | NR                  |
| Ni et al., 2018     | 2018/11/26          | 2018/03/03                    | 19(19)                       | High dose: ≥300 mg/day; Low dose: <300 mg/day | NR                  |

RCTs, Randomized controlled trials; NR, Not reported. Unclear, The definitions of dose or course were not reported in systematic reviews and meta-analyses. *indicates that including 17 RCTs, 3 quasi-randomized trials and 2 conference proceedings. Short-term, high-dose intravenous methylprednisolone (30 mg/kg every 6 h for 4 doses or a 30-mg/kg bolus followed by a 5-mg/kg/h infusion for 9 h).

FIGURE 1 | Flow diagram of searches.
TABLE 2 | Application of AMSTAR 2.

| Items of AMSTAR 2                                                                 | Annane et al., 2004 | Bury and Wax, 2004 | Minneci et al., 2004 | Annane et al., 2009 | Sigl et al., 2009 | Moran et al., 2010 | Wang et al., 2014 | Volbeda et al., 2015 | Annane et al., 2015 | Rochwerg et al., 2018 | Rygard et al., 2018 | Xu et al., 2018 | Zhu et al., 2018 | Fang et al., 2019 | Lyu et al., 2018 | Ni et al., 2018 |
|----------------------------------------------------------------------------------|---------------------|--------------------|----------------------|---------------------|-------------------|-------------------|-------------------|---------------------|---------------------|----------------------|----------------------|----------------|---------------|----------------|----------------|----------------|
| 1. Did the research questions and inclusion criteria for the review include the components of PICO? | Y                   | Y                  | Y                    | Y                   | Y                  | Y                 | Y                 | Y                   | Y                   | Y                    | Y                    | Y               | Y             | Y              | Y              | Y              |
| 2. Did the report of the review contain an explicit statement that the review methods were established prior to the conduct of the review and did the report justify any significant deviations from the protocol? | P                   | P                  | Y                    | P                   | P                  | P                 | P                 | P                   | Y                   | Y                    | Y                    | Y               | Y             | Y              | Y              | Y              |
| 3. Did the review authors explain their selection of the study designs for inclusion in the review? | Y                   | U                  | U                    | Y                   | U                  | Y                 | U                 | U                   | Y                   | U                    | Y                    | Y               | Y             | Y              | Y              | Y              |
| 4. Did the review authors use a comprehensive literature search strategy?          | Y                   | Y                  | P                    | Y                   | Y                  | Y                 | Y                 | Y                   | Y                   | Y                    | Y                    | Y               | Y             | Y              | Y              | Y              |
| 5. Did the review authors perform study selection in duplicate?                    | Y                   | Y                  | Y                    | Y                   | Y                  | Y                 | Y                 | Y                   | Y                   | Y                    | Y                    | Y               | Y             | Y              | Y              | Y              |
| 6. Did the review authors perform data extraction in duplicate?                    | Y                   | Y                  | Y                    | Y                   | Y                  | Y                 | Y                 | Y                   | Y                   | Y                    | Y                    | Y               | Y             | Y              | Y              | Y              |
| 7. Did the review authors provide a list of excluded studies and justify the exclusions? | Y                   | N                  | N                    | Y                   | Y                  | Y                 | Y                 | Y                   | N                   | N                    | N                    | N               | N             | N              | N              | N              |
| 8. Did the review authors describe the included studies in adequate detail?        | Y                   | N                  | Y                    | P                   | Y                  | P                 | Y                 | Y                   | P                   | P                    | P                    | Y               | Y             | Y              | Y              | Y              |
| 9. Did the review authors use a satisfactory technique for assessing the risk of bias (RoB) in individual studies that were included in the review? | Y                   | Y                  | Y                    | Y                   | Y                  | Y                 | Y                 | Y                   | Y                   | Y                    | Y                    | Y               | Y             | Y              | Y              | Y              |
| 10. Did the review authors report on the sources of funding for the studies included in the review? | N                   | N                  | N                    | N                   | N                  | N                 | N                 | N                   | N                   | N                    | N                    | N               | N             | N              | N              | N              |
| 11. If meta-analysis was performed, did the review authors use appropriate methods for statistical combination of results? | Y                   | Y                  | Y                    | Y                   | Y                  | Y                 | Y                 | Y                   | Y                   | Y                    | Y                    | Y               | Y             | Y              | Y              | Y              |
| 12. If meta-analysis was performed, did the review authors assess the potential impact of RoB in individual studies on the results of the meta-analysis or other evidence synthesis? | Y                   | Y                  | Y                    | Y                   | Y                  | Y                 | Y                 | Y                   | Y                   | Y                    | Y                    | Y               | Y             | Y              | Y              | Y              |
| 13. Did the review authors account for RoB in primary studies when interpreting/discussing the results of the review? | N                   | N                  | N                    | Y                   | N                  | N                 | Y                 | Y                   | Y                   | Y                    | Y                    | Y               | Y             | Y              | Y              | N              |
| 14. Did the review authors provide a satisfactory explanation for, and discussion of, any heterogeneity observed in the results of the review? | Y                   | N                  | Y                    | Y                   | Y                  | Y                 | Y                 | Y                   | Y                   | Y                    | Y                    | Y               | Y             | Y              | Y              | Y              |
| 15. If they performed quantitative synthesis did the review authors carry out an adequate investigation of publication bias (small study bias) and discuss its likely impact on the results of the review? | Y                   | N                  | N                    | Y                   | Y                  | Y                 | Y                 | Y                   | Y                   | Y                    | Y                    | Y               | Y             | Y              | Y              | N              |
| 16. Did the review authors report any potential sources of conflict of interest, including any funding they received for conducting the review? | Y                   | U                  | Y                    | U                   | Y                  | Y                 | Y                 | Y                   | Y                   | Y                    | Y                    | Y               | Y             | Y              | Y              | Y              |

AMSTAR 2, A MeaSurement Tool to Assess systematic Reviews; Y, Yes; N, No; P, Partial Yes; U, Unclear.
the results of each review using a checklist from the AMSTAR website (www.amstar.ca). Meanwhile, the quality of each meta-analysis and systematic review was examined using the AMSTAR 2 tool. We found that the study by Fang et al met the 14 items of the AMSTAR instrument and most likely offered the most comprehensive meta-analysis of the role of corticosteroids in sepsis and septic shock. ROBIS endorses domain-based approaches for integral systematic reviews in a similar manner to AMSTAR 2, and judges risk of bias in the review process, results and conclusion as “low,” “high,” or “unclear,” and guides recommendations to improve patient care. These results are presented in a tabular graph (Table 3).

**Heterogeneity Assessment**

Of the 16 systematic reviews and meta-analyses that were included in this overlapping review (Annane et al., 2004; Burry and Wax, 2004; Minneci et al., 2004; Annane et al., 2009; Sligl et al., 2009; Moran et al., 2010; Wang et al., 2014; Volbeda et al., 2015; Annane et al., 2015; Lyu et al., 2018; Ni et al., 2018; Rochwerg et al., 2018; Rygard et al., 2018; Xu et al., 2018; Zhu et al., 2018; Fang et al., 2019), 15 studies (Annane et al., 2004; Minneci et al., 2004; Annane et al., 2009; Sligl et al., 2009; Moran et al., 2010; Wang et al., 2014; Annane et al., 2015; Volbeda et al., 2015; Lyu et al., 2018; Ni et al., 2018; Rochwerg et al., 2018; Rygard et al., 2018; Xu et al., 2018; Zhu et al., 2018; Fang et al., 2019) performed and reported statistical heterogeneity analysis, and only one study (Burry and Wax, 2004) discussed, but did not analyze, descriptive data. All of the 17 studies (Annane et al., 2004; Burry and Wax, 2004; Minneci et al., 2004; Annane et al., 2009; Sligl et al., 2009; Moran et al., 2010; Wang et al., 2014; Annane et al., 2015; Volbeda et al., 2015; Lyu et al., 2018; Ni et al., 2018; Rochwerg et al., 2018; Rygard et al., 2018; Xu et al., 2018; Zhu et al., 2018; Fang et al., 2019) carried out primary study quality and showed the relevant data from individual studies.

With respect to the size of the primary studies, Seven studies (Minneci et al., 2004; Moran et al., 2010; Wang et al., 2014; Lyu et al., 2018; Ni et al., 2018; Zhu et al., 2018; Fang et al., 2019) reported and analyzed this parameter; three systematic reviews (Burry and Wax, 2004; Annane et al., 2015; Volbeda et al., 2015) discussed it, but did not present concrete data, while the rest of systematic reviews (Annane et al., 2004; Annane et al., 2009; Sligl et al., 2009; Rochwerg et al., 2018; Rygard et al., 2018; Xu et al., 2018) did not conduct a formal sensitivity or subgroup analysis.

**STUDY RESULT**

**Primary Outcome**

Almost all of studies included a 28-day mortality after corticosteroids therapy (Annane et al., 2004; Burry and Wax, 2004; Minneci et al., 2004; Annane et al., 2009; Sligl et al., 2009; Moran et al., 2010; Wang et al., 2014; Annane et al., 2015; Lyu et al., 2018; Ni et al., 2018; Rochwerg et al., 2018; Rygard et al., 2018; Xu et al., 2018; Zhu et al., 2018; Fang et al., 2019). Different viewpoints were presented across different meta-analyses about whether different doses of corticosteroids (especially on long course of corticosteroids therapy) could decrease the 28-day mortality. A couple of studies found that 28-day all-cause mortality didn’t show a significant effect, and a high or low dose of corticosteroids...
for sepsis or septic shock, did not show a significant effect either (Sligl et al., 2009; Volbeda et al., 2015; Lyu et al., 2018; Ni et al., 2018; Rochwerg et al., 2018; Zhu et al., 2018), while others held the opposite view (Annane et al., 2004; Annane et al., 2009; Annane et al., 2015; Fang et al., 2019). Ninety-day mortality was also listed as primary outcomes, in which two studies presented similar data (Zhu et al., 2018; Fang et al., 2019), while three studies offered relevant data (Volbeda et al., 2015; Zhu et al., 2018; Fang et al., 2019). Furthermore, short-term and long-term mortality were divided based on the different standards of three studies (Rochwerg et al., 2018; Rygard et al., 2018; Fang et al., 2019), all published in 2018 and 2019. The details of mortality based on different days are shown in Figure 2.

### Mortality of Hospital and ICU

A total of six studies (Annane et al., 2004; Annane et al., 2009; Annane et al., 2015; Lyu et al., 2018; Zhu et al., 2018; Fang et al., 2019) reported the outcome of hospital mortality and of those, three studies (Annane et al., 2004; Annane et al., 2009; Zhu et al., 2018) demonstrated no significant impact on hospital mortality using corticosteroids for patients with sepsis and septic shock. All of these studies performed a subgroup analysis based on duration and dose, and the results of this outcome are described in Figure 3. Additionally, six studies paid particular attention to ICU mortality (Annane et al., 2004; Annane et al., 2009; Annane et al., 2015; Lyu et al., 2018; Zhu et al., 2018; Fang et al., 2019), and two (Annane et al., 2009; Lyu et al., 2018) of the six studies

![FIGURE 2](image_url) Forest plot of mortality according to days ranked in ascending order (fourteen days to one year) with different courses in diverse dose (long course of low dose corticosteroids and short course of high dose corticosteroids).
kept an eye on ICU mortality on a long course of low-dose corticosteroids.

**Length of Stay in ICU and Hospital**

The length of stay in the ICU was reported by six studies (Annane et al., 2009; Annane et al., 2015; Lyu et al., 2018; Rochwerg et al., 2018; Rygard et al., 2018; Fang et al., 2019) and three studies reported the length of stay in the hospital (Annane et al., 2015; Rochwerg et al., 2018; Rygard et al., 2018). Only a few studies published in 2018 and 2019 carried out a subgroup analysis on a long course of low dose corticosteroids (Zhu et al., 2018; Fang et al., 2019) (see Figure 4).

**Shock Reversal**

Shock reversal was stratified into two cohorts, shock reversal at day 7 and day 28. Twelve studies compared a treatment group (corticosteroids treatment) and control group (placebo or standard treatment)(Annane et al., 2004; Minneci et al., 2004; Annane et al., 2009; Sligl et al., 2009; Moran et al., 2010; Annane et al., 2015; Rochwerg et al., 2018; Zhu et al., 2018; Fang et al., 2019). Seven of the nine studies performed a further subgroup analysis of a long course of low-dose corticosteroids, and found that low-dose corticosteroids over a long course, contributed to shock reversal at day 7 (Annane et al., 2004; Annane et al., 2009; Moran et al., 2010; Annane et al., 2015; Rochwerg et al., 2018; Zhu et al., 2018; Fang et al., 2019). As such, Wang et al (Wang et al., 2014) presented a subgroup analysis of shock reversal at day 28 for a long course of low dose corticosteroids. All of details about the shock reversal are illustrated in Figure 5.

**Adverse Events**

A total of 10 types of adverse events associated with corticosteroids were analyzed by the included studies in this overlapping meta-analysis. Gastroduodenal bleeding, superinfection, hyperglycemia and hypernatraemia were the most common adverse events and were reported and discussed by almost all of the studies included. Other outcomes of the adverse events reported, are fully described in Figure 6.
### FIGURE 4
Forest plot of the length of patients stay in ICU and hospital by subgroup analysis based on long course of low dose corticosteroids and short course of high dose corticosteroids.

| Study or Subgroup | Mean Difference | SE | IV, Fixed, 95% CI | Year |
|-------------------|----------------|----|-------------------|------|
| **1.3.1 Length of stay in the ICU** | | | | |
| Annane-o 2009 | -4.49 | 1.30 | 102 | -4.49 [1.04, -1.94] | 2009 |
| Annane-q 2015 | -1.98 | 0.81 | 224 | -1.69 [1.37, -0.09] | 2015 |
| Rygard-g 2018 | -0.75 | 0.38 | 5204 | -0.75 [0.50, 0.00] | 2018 |
| Rochwerg-j 2018 | -0.73 | 0.53 | 163 | -0.73 [1.77, 0.31] | 2018 |
| Lyu 2018 | -0.66 | 0.69 | 1327 | -0.66 [-2.01, 0.69] | 2018 |
| Fang 2019 | -1.16 | 0.49 | 796 | -1.16 [2.12, -0.20] | 2019 |

### FIGURE 5
Forest plot of reversal of shock at day 7 and day 28 by subgroup analysis based on long course of low dose corticosteroids and short course of high dose corticosteroids.

| Study or Subgroup | Risk Ratio | SE | IV, Fixed, 95% CI | Year |
|-------------------|------------|----|-------------------|------|
| **1.4.1 Shock reversal at day 7 on short course of high dose corticosteroids** | | | | |
| Moran-d 2010 | 0.0751 017 | 0.84 | 824 | 1.08 [0.20, 5.68] | 2010 |
| Annane-j 2015 | 0.0676 59 | 0.26 | 2373 | 1.07 [0.64, 1.79] | 2015 |
| Zhu 2018 | 0.0676 59 | 0.26 | 2373 | 1.07 [0.64, 1.79] | 2018 |

### FIGURE 5
Forest plot of reversal of shock at day 7 and day 28 by subgroup analysis based on long course of low dose corticosteroids and short course of high dose corticosteroids.

| Study or Subgroup | Risk Ratio | SE | IV, Fixed, 95% CI | Year |
|-------------------|------------|----|-------------------|------|
| **1.4.2 Shock reversal at day 7 on long course of low dose corticosteroids** | | | | |
| Annane-h 2004 | 0.4700 04 | 0.11 | 9648 | 1.60 [1.27, 2.02] | 2004 |
| Annane-h 2009 | 0.3001 05 | 0.07 | 208 | 1.35 [1.16, 1.57] | 2009 |
| Moran-c 2010 | 0.69 | 264 | 7 | 1.00 [0.97, 1.12] | 2010 |
| Wang-a 2014 | 0.7314 06 | 0.13 | 909 | 2.08 [1.58, 2.73] | 2014 |
| Annane-i 2015 | 0.2926 | 0.05 | 813 | 1.34 [1.22, 1.47] | 2015 |
| Lyu 2018 | 0.2851 79 | 0.13 | 3296 | 1.33 [1.02, 1.73] | 2018 |
| Zhu 2018 | 0.3364 72 | 0.18 | 3249 | 1.20 [0.98, 2.00] | 2018 |
| Xu 2018 | 0.3074 85 | 0.06 | 3038 | 1.36 [1.20, 1.54] | 2018 |

### FIGURE 5
Forest plot of reversal of shock at day 7 and day 28 by subgroup analysis based on long course of low dose corticosteroids and short course of high dose corticosteroids.
FIGURE 6 | Forest plot of adverse events by subgroup analysis based on long course of low dose corticosteroids and short course of high dose corticosteroids.
**Application of Jadad Decision Algorithm**

The Jadad Decision Algorithm was applied to identify which meta-analyses offered the best evidence among the included studies and was dependently implemented by two lead authors. A meta-analysis provided the highest level of currently available evidence (Fang et al., 2019), based on the Jadad Decision Algorithm, and found that patients with septic shock or sepsis who used a long course of low dose corticosteroids tended to benefit, as manifested by a decreased mortality of 28 days (Figure 7).

**DISCUSSION**

Whether corticosteroids have an effect on sepsis and septic shock remains unclear and a definite conclusion has not been achieved. This overlapping meta-analysis probed the efficacy and safety of corticosteroids for sepsis and septic shock and sought to identify the reason for discordance across the various meta-analyses, as the most comprehensive overlapping meta-analysis performed to date. Multiple studies, that included meta-analyses and systematic reviews (Annane et al., 2004; Burry and Wax, 2004; Minneci et al., 2004; Annane et al., 2009; Sligl et al., 2009; Moran et al., 2010; Wang et al., 2014; Annane et al., 2015; Rochwerger et al., 2018; Rygard et al., 2018; Xue et al., 2018; Zhu et al., 2018) and primary studies (Cohen et al., 2015; Annane et al., 2017; Long and Koyfman, 2017; Annane et al., 2018; Makic and Bridges, 2018), were explored this investigation. A detailed elaboration of diverse doses and length of corticosteroids administration for patients who suffer from sepsis and septic shock was investigated in a meta-analysis by Fang et al. We selected the current best meta-analyses and systematic reviews using several methodologic appraisal tools (AMSTAR 2, ROBIS, and Jadad decision algorithm). Using these assessment tools, we found the meta-analysis with the highest and best level of evidence (Fang et al., 2019).

There are 16 studies included in this article (Annane et al., 2004; Burry and Wax, 2004; Minneci et al., 2004; Annane et al., 2009; Sligl et al., 2009; Moran et al., 2010; Annane et al., 2015; Lyu et al., 2018; Xue et al., 2018; Rochwerger et al., 2018; Rygard et al., 2018; Xue et al., 2018; Zhu et al., 2018; Fang et al., 2019), almost all of which reported 28-day mortality and discussed this outcome. The key study by Fang et al compared a long course of low dose corticosteroids and a short course of high dose corticosteroids and concluded that the 28-day mortality rate improved after the administration of a long course of low-dose corticosteroids. Moreover, the 28-day mortality after a long courses of low dose corticosteroids, has shown discrepancies among the four meta-analyses that were published in 2018 and 2019 (Lyu et al., 2018; Xue et al., 2018; Zhu et al., 2018; Fang et al., 2019). It all boils down to two respects.
that included participant characteristic and included primary studies. A 90-day mortality appeals to more researchers, and it might be vital evidence to reflect the validity of applying a long course of low dose corticosteroids for sepsis and septic shock. Recent reviews of corticosteroids have reached a consensus that a 90-day mortality had no improvement for patients who received treatment of a long course of low dose corticosteroids (Volbeda et al., 2015; Zhu et al., 2018; Fang et al., 2019).

With respect to the terms of mortality, a 90-day mortality cut-off point was used by Rygard et al. (Rygard et al., 2018) and Fang et al. (Fang et al., 2019). Different to Rygard et al. (Rygard et al., 2018) and Fang et al (Fang et al., 2019), Rochwerg et al. (Rochwerg et al., 2018) investigated 60 days to 1 year mortality as a long term mortality and marked 28-day to 31-day mortality as a short term mortality caused by sepsis and septic shock.

In contrast to other studies that reported hospital mortality, Annane et al. (2015), Fang et al. (2019) and Lyu et al. (2018) provided data that favors corticosteroids. The study with the current best available evidence demonstrated that a long course of low-dose corticosteroids could improve ICU mortality (Fang et al., 2019). Shock reversal was one a beneficial outcome, occurring as early as 2004, by Annane et al. (2004). Eight studies presented the idea that shock reversal at day 7 could benefit from the treatment of corticosteroids (Annane et al., 2004; Minneci et al., 2004; Annane et al., 2009; Sligl et al., 2009; Moran et al., 2010; Annane et al., 2015; Rochwerg et al., 2018; Zhu et al., 2018). Furthermore, three studies by Annane et al published in 2004, 2009 and 2015 reported the reversal of shock at day 28, which displayed a positive effect that favors corticosteroids (Annane et al., 2004; Annane et al., 2009; Annane et al., 2015).

The length of stay in the ICU and hospital also reflect the benefits of corticosteroids for patients who develop sepsis and septic shock. A recent meta-analyses of corticosteroids disclosed the details of results of the length of stay in the ICU and hospital, and the findings of these studies were so divergent that we could ultimately draw the conclusion that corticosteroids have no immediate benefit on the length of stay in the hospital (Annane et al., 2009; Annane et al., 2015; Lyu et al., 2018; Rochwerg et al., 2018; Rygard et al., 2018; Zhu et al., 2018) but benefit the length of stay in the ICU (Annane et al., 2009; Annane et al., 2015; Fang et al., 2019). The severity of adverse events is likely to increase mortality and affects the application of corticosteroids for participants with sepsis and septic shock. We found that regardless of the dose and course duration of corticosteroids, the incidence of gastroduodenal bleeding did not significantly increase. Nine studies elaborated no striking impact on superinfection or secondary infection apropos of high dose corticosteroids, as well as a long course of low dose corticosteroids (Annane et al., 2004; Annane et al., 2009; Sligl et al., 2009; Annane et al., 2015; Lyu et al., 2018; Rochwerg et al., 2018; Rygard et al., 2018; Zhu et al., 2018; Fang et al., 2019).

At present, the guidelines of sepsis management that were updated in 2013 advocate that corticosteroids that are used in the context of adequate fluid resuscitation and vasoressor treatment, have the capability of restoring hemodynamic stability (Dellinger et al., 2013). The newest guidelines by Rhodes et al further demonstrated that both agreed with hydrocortisone therapy at 200 mg per day (Rhodes et al., 2017).

LIMITATIONS

The originality and importance of this overlapping meta-analysis is with respect to its exploration of comprehensive outcomes to determine whether corticoid steroid therapy is harmful or beneficial for patients with sepsis and septic shock. We provide insights into the existing differences among various metanalyses and systematic reviews and offer relevant suggestions about strategies for using corticosteroids. Additionally, we used the newest methodologic assessment tools including AMSTAR 2 and ROBIS, which were published in 2017 and 2016, respectively. These could better comprehensively assess the meta-analyses and systematic reviews included, acquiring the current best available evidence. The 28-day mortality with the use of a long course of low-dose corticosteroids was in the list of critical aspects and was discussed and analyzed. In addition, we conducted heterogeneity and subgroup analyses of the primary studies to better reveal the sources of heterogeneity from the primary studies. We only included 16 systematic reviews and meta-analyses that met our eligibility criteria and hope that more studies can be included in the future. Only RCTs were included in this study. Furthermore, there was insufficient data of mortality on 90 days or longer periods, owing to the fact that fewer studies reported these statistics. Understanding the link between corticosteroids, sepsis and septic shock will help clinical staff and decision-makers in ensuring optimal care for patients who receive long courses of low-dose corticosteroid therapy.

The following aspects need to be investigated in the future: (1) First, the accurate dose for distinguishing high and low doses, as well as short- and long-courses, has not been resolved at present. The included studies have their own classification standards about doses and terms. (2) As such, the optimal strategy of involving corticosteroids dosage and preferred glucocorticoid remains ambiguous. These issues could have influenced the result of corticosteroids for sepsis and sepsis shock.

CONCLUSION

A comparison of the findings across studies has allowed us to confirm that a long course of low-dose corticosteroids contribute in reducing 28-day mortality, mortality of ICU and hospital stays and the length of stay in the ICU for patients undergoing therapy for sepsis and septic shock. However, no improvement was found in long-term mortality outcomes, such as 90-day mortality. Concerning adverse events, except for hyperglycemia and hypernatraemia, no other significant improvement was observed.

AUTHOR CONTRIBUTIONS

CZ and Y-MN conceptualized and coordinated the study. CZ drafted the initial protocol. Y-MN developed the search strategy. L-LL, Y-YY, and H-YG screened citations and assessed studies for eligibility. L-LL and Y-YY extracted data. H-YG and J-YW performed quality assessments. Y-YY and J-YW provided content expertise in corticosteroids and Sepsis/Septic Shock. CZ and Y-MN provided methodologic expertise in knowledge synthesis.
and resolved disagreements regarding study eligibility or quality assessments. CZ, Y-MN, and L-LL critically reviewed the manuscript for important intellectual content. All of the authors provided final approval of the version to be published and agreed to be accountable for all aspects of the work.

REFERENCES

Angus, D. C., Linde-Zwirble, W. T., Lidicker, J., Clermont, G., Carcillo, J., and Pinsky, M. R. (2001). Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 29, 1303–1310. doi: 10.1097/00003246-200107000-00002

Annan, D., Bellissant, E., Bollaert, P. E., Brriegel, J., Confalonieri, M., De Gaudio, R., et al. (2009). Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review. JAMA 301 (22), 2362–2375. doi: 10.1001/jama.2009.815

Annan, D., Bellissant, E., Bollaert, P. E., Brriegel, J., Keh, D., and Kupfer, Y. (2004). Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis. BMJ 329, 480. doi: 10.1136/bmj.38181.482222.55

Annan, D., Bellissant, E., Bollaert, P. E., Brriegel, J., Keh, D., and Kupfer, Y. (2015). Corticosteroids for treating sepsis. Cochrane Database Syst. Rev., CD002243. doi: 10.1002/14651858.CD002243.pub3

Annan, D., Pastores, S. M., Arlt, W., Balk, R. A., Beishuizen, A., Brriegel, J., et al. (2017). Critical Illness-Related Corticosteroid Insufficiency (CIRCI): a narrative review from a Multispecialty Task Force of the Society of Critical Care Medicine (SCCM) and the European Society of Intensive Care Medicine (ESICM). Crit. Care Med. 45, 2089–2098. doi: 10.1097/CCM.0000000000002274

Annan, D., Renault, A., Brun-Buisson, C., Meregarean, B., Quenet, J. P., Siami, S., et al. (2018). Hydrocortisone plus fludrocortisone for adults with septic shock. N. Engl. J. Med. 378, 809–818. doi: 10.1056/NEJMoa1705716

Authors, N. (1987). Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N. Engl. J. Med. 317, 659–665. doi: 10.1056/NEJM198709103171102

Bone, R. C., Fisher, C. J., Jr., Clemmer, T. P., Slotman, G. J., Metz, C. A., and Balk, R. A. (1987). A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N. Engl. J. Med. 317, 653–658. doi: 10.1056/NEJM198709103171101

Burry, L. D., and Wax, R. S. (2004). Role of corticosteroids in septic shock. Ann. Pharmacother. 38, 464–472. doi: 10.1345/aph.1C435

Cawcutt, K. A., and Peters, S. G. (2014). Severe sepsis and septic shock: clinical overview and update on management. Mayo Clin. Proc. 89, 1572–1578. doi: 10.1016/j.mayocp.2014.07.009

Cohen, J., Vincent, J. L., Adhikari, N. K., Suter, M., Bone, R. C., et al. (2016). Developing a new definition and assessing new clinical criteria for sepsis: for the third international consensus definitions for sepsis and septic shock (Sepsis-3) conference. Crit. Care Med. 44, 300–317. doi: 10.1097/CCM.0000530223.33211.f5

Corticosteroids for Sepsis and Septic Shock

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2019.00714/full#supplementary-material
Corticosteroids for Sepsis and Septic Shock

Yao et al.

Frontiers in Pharmacology | www.frontiersin.org 14 July 2019 | Volume 10 | Article 714

shock. A prospective, controlled study. *N. Engl. J. Med.* 311, 1137–1143. doi: 10.1056/NEJM198411013111801

Suffredini, A. F., and Munford, R. S. (2011). Novel therapies for septic shock over the past 4 decades. *JAMA* 306, 194–199. doi: 10.1001/jama.2011.909

Volbeda, M., Witterslev, J., Gliud, C., Zijlstra, J. G., van der Horst, I. C., and Keus, F. (2015). Glucocorticosteroids for sepsis: systematic review with meta-analysis and trial sequential analysis. *Intensive Care Med.* 41, 1220–1234. doi: 10.1007/s00134-015-3899-6

Wang, C., Sun, J., Zheng, J., Guo, L., Ma, H., Zhang, Y., et al. (2014). Low-dose hydrocortisone therapy attenuates septic shock in adult patients but does not reduce 28-day mortality: a meta-analysis of randomized controlled trials. *Anesth. Analg.* 118, 346–357. doi: 10.1213/ANE.0000000000000050

Whiting, P., Savovic, J., Higgins, J. P., Caldwell, D. M., Reeves, B. C., Shea, B., et al. (2016). ROBIS: a new tool to assess risk of bias in systematic reviews was developed. *J. Clin. Epidemiol.* 69, 225–234. doi: 10.1016/j.jclinepi.2015.06.005

Xu, R., Wang, Q., Huang, Y., Wu, L., Liu, Q., Hu, W., et al. (2018). Do low-dose corticosteroids improve survival or shock reversal from septic shock in adults? Meta-analysis with trial sequential analysis. *J. Int. Med. Res.* 46, 2513–2524. doi: 10.1177/0300060518774985

Zhu, Y., Wen, Y., Jiang, Q., Guo, N., Cai, Y., and Shen, X. (2018). The effectiveness and safety of corticosteroids therapy in adult critical ill patients with septic shock: a meta-analysis of randomized controlled trials. *Shock* doi: 10.1097/ SHK.0000000000001202.

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Yao, Lin, Gu, Wu, Niu and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.